TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis by Arbués, Ainhoa et al.
RESEARCH ARTICLE
TNF-α antagonists differentially induce TGF-
β1-dependent resuscitation of dormant-like
Mycobacterium tuberculosis
Ainhoa Arbue´s1,2, Dominique Brees3, Salah-Dine Chibout3, Todd Fox4,
Michael Kammu¨llerID3*, Damien PortevinID1,2*
1 Department of Medical Parasitology & Infection Biology, Swiss Tropical and Public Health Institute, Basel,
Switzerland, 2 University of Basel, Basel, Switzerland, 3 Novartis Institutes for Biomedical Research, Basel,
Switzerland, 4 Novartis Pharma AG, Basel, Switzerland
* michael.kammueller@novartis.com (MK); damien.portevin@swisstph.ch (DP)
Abstract
TNF-α- as well as non-TNF-α-targeting biologics are prescribed to treat a variety of
immune-mediated inflammatory disorders. The well-documented risk of tuberculosis pro-
gression associated with anti-TNF-α treatment highlighted the central role of TNF-α for the
maintenance of protective immunity, although the rate of tuberculosis detected among
patients varies with the nature of the drug. Using a human, in-vitro granuloma model, we
reproduce the increased reactivation rate of tuberculosis following exposure to Adalimumab
compared to Etanercept, two TNF-α-neutralizing biologics. We show that Adalimumab,
because of its bivalence, specifically induces TGF-β1-dependent Mycobacterium tuberculo-
sis (Mtb) resuscitation which can be prevented by concomitant TGF-β1 neutralization. More-
over, our data suggest an additional role of lymphotoxin-α–neutralized by Etanercept but not
Adalimumab–in the control of latent tuberculosis infection. Furthermore, we show that, while
Secukinumab, an anti-IL-17A antibody, does not revert Mtb dormancy, the anti-IL-12-p40
antibody Ustekinumab and the recombinant IL-1RA Anakinra promote Mtb resuscitation, in
line with the importance of these pathways in tuberculosis immunity.
Author summary
Mycobacterium tuberculosis (Mtb) is the world’s leading infectious killer. Multi-cellular
immune structures called granulomas may constitute a latent form of Mtb infection and a
potential reservoir for future cases. Post-marketing surveillance data suggested that Mtb
protective immunity is unequally impacted by different TNF-α-targeting drugs used to
treat inflammatory disorders. We used an in-vitro granuloma model to reproduce these
clinical observations and gain mechanistic insights and, in addition, to assess the risk of
tuberculosis reactivation associated with the use of other immunomodulatory drugs.
These results may inspire pharmacologists to design future drug-development strategies
of biologics in particular, while immunologists and microbiologists will find a relevant
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experimental approach to disentangle the complex interactions involved in Mtb protective
immunity and immunopathogenesis.
Introduction
Tuberculosis (TB) remains the leading cause of deaths worldwide due to a single infectious
agent. In addition, it is estimated that a quarter of the world’s population presents an immune
memory against Mycobacterium tuberculosis (Mtb)-specific antigens in the absence of clinical
symptoms, and is thus inferred to be latently infected. Therefore, so-defined latent TB infec-
tion (LTBI) does not necessarily reflect the presence of a continued Mtb infection as it encom-
passes cured as well quiescent, asymptomatic or subclinical infections [1]. Recent Mtb
infection in high-transmission areas is the major contributor to the global TB burden [2]. Yet,
in low endemic countries, the risk of progressing from latent to active TB can reach up to 10%
if the immune system is weakened, e.g. as a consequence of HIV co-infection or immunosup-
pressive drug treatments.
The hallmark of the host immune response against the tubercle bacillus is the formation of
structurally-organized, multicellular clusters constituted mainly of macrophages and lympho-
cytes called granulomas. Despite having the potential to be sterilizing, in some instances gran-
ulomas may contain but not eliminate the infection. Current thinking holds that immune
activation and hypoxia within granulomas favor a switching of mycobacterial physiology into
a lipid-rich, low-metabolic, and potentially non-replicating, dormant state that may persist for
decades. Consequently, dormant Mtb displays an increased tolerance to antibiotics that target
metabolic pathways active during bacterial replication [3,4]. The complex pathophysiology of
Mtb infection suscitated the need to define an appropriate terminology. While latency and
reactivation respectively refer to absence or presence of clinical symptoms, dormancy and
resuscitation describe bacterial phenotypes characterized by repressed or revived levels of rep-
lication and metabolic activity, respectively [5,6]. The metabolic switch leading to dormancy
or non-replicating persistence can be induced in vitro upon exposure to various stresses
including hypoxia. Under hypoxic conditions Mtb accumulates intracellular triacylglycerides
into lipid inclusions, and undergoes transcriptional changes leading to a shift in carbon and
energy metabolism [7].
A well-established host factor controlling Mtb dormancy is tumor necrosis factor (TNF)-α,
as documented by the clinical association of anti-TNF-α therapies with reactivation of LTBI
[8]. TNF-α is a homo-trimeric cytokine produced by a variety of immune cells with pleiotropic
functions essential for the control of mycobacterial infections [9,10]. It promotes control of
Mtb intracellular growth within phagocytes [11,12], and also contributes to cell recruitment
and consequently, granuloma formation [13]. TNF-α is initially produced as a transmembrane
form (tmTNF-α) which can then be released upon specific enzymatic activity mediated by the
TNF-α converting enzyme (TACE) [14]. tmTNF-α also plays a role in the inflammatory
response signaling either directly into TNF receptor-bearing cells, and also reciprocally trans-
mitting outside-to-inside (reverse) signals into tmTNF-α-expressing cells themselves [15].
Various biological drugs targeting TNF-α are currently used for the treatment of immune-
mediated inflammatory disorders. These encompass notably infliximab (IFX), a humanized
mouse monoclonal antibody; adalimumab (ADA), a fully-human monoclonal antibody; and
etanercept (ETA), a soluble form of the human TNF-α receptor type II (TNFR2) fused to an
Fc fragment. The fact that treatment with TNF-α-targeting biologics increases the risk of TB
was observed shortly after their licensing 20 years ago [16]. However, post-marketing
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surveillance data suggested that treatment with anti-TNF-α antibodies induces higher LTBI
reactivation rate in comparison to ETA [17]. A major difference between the two types of
TNF-α antagonists resides in their binding properties. On the one hand, antibodies, such as
IFX and ADA, bear two binding sites. Consequently, up to three IFX molecules can be bound
to a single TNF-α homotrimer and only TNF-α-targeting antibodies can mediate reverse sig-
nals through clustering of tmTNF-α [18]. On the other hand, TNFR2, and therefore ETA, can
only interact with one single molecule of TNF-α at a time. Moreover, TNFR2 also binds TNF-
β (more commonly referred to as lymphotoxin (LT)-α) and, as a consequence, ETA bioactivity
may potentially account for the neutralization of both TNFR2 ligands [19].
To date, most studies investigating the immunological mechanisms responsible for the
induction of LTBI reactivation have focused on individual TNF-α blockers [20]. Only few
authors have performed comparative studies aiming to elucidate the mechanisms behind the
differential risk observed between anti-TNF-α antibodies and the receptor fusion protein. Har-
ris et al. showed that only IFX and ADA, but not ETA, inhibited the maturation of Mtb-con-
taining phagosomes in primary human macrophages [21]. Hamdi and collaborators observed
that all three TNF-α-targeting biologics inhibited Mtb-specific CD4+ T-cell proliferation from
LTBI patients, although ETA was less potent [22]. Finally, the mathematical design of in-silico
granulomas suggested that differences in drug binding kinetics and vascular permeability
could explain the differential rates of TB reactivation associated with the different TNF-α-tar-
geting biologics [23,24].
Several TNF-α- and non-TNF-α-targeting biotherapeutics have expanded the pharmaceuti-
cal arsenal for the treatment of immune-mediated inflammatory disorders. The historical con-
cern arising from the post-marketing surveillance of TNF-α antagonists has brought justified
cautiousness concerning potentially impaired protective immune responses against Mtb infec-
tion by these novel biotherapeutics [25]. Hence, the development of tools able to predict TB
infection risk in patients treated with biologics could substantially impact the clinical manage-
ment of the respective disease and as such, benefit both physicians and patients, as well as con-
tribute to a refined understanding of TB protective immunity.
Over the last decade, several independent laboratories described in-vitro granuloma models
that reflect the organization of human nascent granulomas orchestrated by relevant cytokines,
and that constitute valuable tools to study key aspects of the interaction of Mtb with the host
immune response [26–30]. To further investigate the differential rate of Mtb resuscitation
observed between TNF-α-inhibitors ADA and ETA, we made use of the three-dimensional
model developed by Kapoor and collaborators and that displayed interesting features of Mtb
associated with dormancy, such as the accumulation of lipid bodies, loss of acid-fastness and
an increase in antibiotic tolerance [4,28]. Noteworthy, this model was also able to reproduce
the induction of Mtb resuscitation upon exposure to a research grade TNF-α-neutralizing
antibody.
In this report, we explore the capability of such human, in-vitro granuloma model to assess
the LTBI-reactivation risk of several TNF-α- and non-TNF-α-targeting biologics licensed for
the treatment of various immune-mediated inflammatory disorders. We demonstrate the rele-
vance of this approach by reproducing a differential rate of Mtb resuscitation in in-vitro granu-
lomas exposed to ADA in comparison to ETA. Finally, we show that the different LTBI-
reactivation rate observed for these two TNF-α-targeting biologics arises from divergent
mechanisms of action: ADA mediates substantial Mtb resuscitation in a TGF-β1-dependent
manner via tmTNF-α reverse signaling, while ETA potentiates a mild resuscitation of Mtb
only through neutralization of TNF-α and, to an unexpected similar extent, LT-α.
TNF-α antagonists and M. tuberculosis resuscitation in granulomas
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Results
Human, in-vitro granulomas mimic dormant-like Mtb features
First of all, we sought to confirm that upon formation of 3D microgranulomas in vitro, Mtb
can exhibit dormancy characteristics such as alteration of gene regulation coupled with the
accumulation of triacylglycerides as intracellular lipid inclusions and loss of acid fastness, as
studied in more detail by the group of Kolattukudy [28]. Peripheral Blood Mononuclear Cells
(PBMCs) isolated from consenting, anonymous healthy blood donors were used. In order to
be able to study the impact of biologics targeting cytokines derived from innate as well as adap-
tive immune responses in this model, only samples displaying significant IFN-γ+ CD4+ T cell
responses against Mtb protein purified derivative (PPD) were included in the study (S1 Fig).
None of the donors displayed signs of LTBI, i.e. a significant response against a synthetic over-
lapping peptide pool covering the sequences of ESAT-6, CFP-10 and two highly immunogenic
peptides of TB7.7 Mtb proteins. This suggests that responses to PPD could be attributed to the
cross-reactivity of antigens delivered through previous M. bovis BCG vaccination and/or to
previous exposure to environmental mycobacteria [31–33]. PBMCs were infected with Mtb
H37Rv and embedded in a matrix of collagen and fibronectin. A representative view of Mtb-
induced granulomas obtained 8 days post-infection is depicted in Fig 1A. However, and as pre-
viously observed [30], granulomas differed in number and size across donors. We used live
cell-tracker dyes to show that these structures consist of monocyte-derived macrophages
(orange) surrounded by T cells (in green) as well as additional unlabeled mononuclear-cell
subsets recalling the organizational features of granulomas in vivo (Fig 1B), as previously
reported for this model [28]. The formation of in-vitro granulomas promoted a significant
accumulation of Mtb harboring a dormant-like phenotype. Compared to Mtb recovered from
day 1 post-infection, the proportion of lipid-rich (Nile red-positive) Mtb increased 8 days
post-infection (Fig 1C). Furthermore, the enriched Nile red-positive Mtb phenotype correlated
with increased transcription levels of icl (isocitrate lyase) and gltA1 (methylcitrate synthase)
and down-regulation of nuoB (NADH dehydrogenase, chain B) and ctaD (cytochrome c oxi-
dase polypeptide I) (Fig 1D), as reported previously by Kapoor et al [28], and corresponding to
transcriptome profiles characteristic of lipid-rich persister-like bacilli found in clinical tuber-
culous sputum [34].
Human, in-vitro granulomas corroborate LTBI reactivation related to
treatment with TNF-α- and some non-TNF-α-targeting biologics
Next, we assessed the capability of some TNF-α- and non-TNF-α-targeting biotherapeutics to
potentially impact Mtb dormancy in this in-vitro granuloma model. We focused our investiga-
tion on cytokine antagonists already licensed for the treatment of immune-mediated inflam-
matory disorders. These encompass ADA, an anti-TNF-α antibody; ETA, a chimeric human
TNFR2 fused to an immunoglobulin Fc fragment; ustekinumab (UST), a human monoclonal
antibody targeting the IL-12p40 subunit, a constituent of both IL-12 and IL-23; anakinra
(ANA), a recombinant, non-glycosylated version of the human IL-1 receptor antagonist (IL-
1RA); and secukinumab (SEK), a human monoclonal anti-IL-17A antibody. Four days post-
infection, nascent granulomas were exposed to equimolar concentrations of each compound
individually, or a human IgG1 isotypic control (Iso). No obvious morphological differences
could be detected between granulomas treated with any of the investigated cytokine antago-
nists compared to the isotype control. Nonetheless, each individual compound differentially
interfered with the capacity of granulomas to maintain Mtb in a dormant-like state (Fig 2A).
ADA induced the highest level of Mtb resuscitation, using as proxy an increase in the
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representation of metabolically-active (auramine-O-positive) bacteria and a concomitant
decrease in the percentage of dormant-like (Nile red-positive) Mtb, compared to the isotype
control. UST and ANA also promoted a marked, comparable reduction in the frequency of
dormant-like bacteria. Interestingly, ETA, despite sharing the same target with ADA, induced
an intermediate level of Mtb resuscitation. SEK behaved as the isotype control, displaying no
Fig 1. Human, in-vitro granulomas mimic dormant-like Mtb features. (A) Representative bright-field microscopy
pictures of 3D in-vitro granulomas formed 8 days post-infection with Mtb H37Rv compared to uninfected PBMCs. (B)
Representative structure of in-vitro granulomas under bright-field (left panel) and fluorescence microscopy (right
panel). Monocytes/macrophages were labeled in orange and CD4+ T cells in green. (C) Percentages of auramine-O-
(green) and Nile red-positive (red) Mtb quantified by fluorescence microscopy (mean ± SEM from 7 independent
donors) before (1 day post-infection) or after (8 days post-infection) granuloma formation. Statistical analysis was
performed using a generalized linear mixed-effects model; ����, p<0.0001. (D) Relative expression values for icl1,
gltA1, nuoB and ctaD after granuloma formation (8 days post-infection) determined by qRT-PCR (mean ± SEM from
4 independent donors). Results are expressed as fold change in log2 scale relative to an aerobically-grown, mid-log Mtb
culture, using 16S rRNA as the endogenous control.
https://doi.org/10.1371/journal.ppat.1008312.g001
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reversal of the mycobacterial dormant-like phenotype into an active state, confirming inde-
pendently the results reported previously [35]. A minor but constant proportion of bacteria
simultaneously stained with both auramine-O and Nile red could be detected in all treatment
groups, likely representing transitional states.
Next, and notably given the lack of activity displayed by SEK, we assessed if the cytokines
targeted by the investigated biologics were being actively produced upon granuloma forma-
tion. Untreated in-vitro granulomas showed the following cytokine levels–median (25th–75th
percentiles)–in the supernatant on day 8 post-infection (Fig 2B): TNF-α 367.8 pg/ml (115.6–
912.1 pg/ml); IL-1β 274.4 pg/ml (138.8–450.4 pg/ml); unexpectedly, and contrasting the major
increase in the proportion of metabolically-active Mtb recovered from granulomas treated
with UST, only low levels of IL-23 (0 pg/ml; 0–23.23 pg/ml) or IL-12p70 (1.713 pg/ml; 1.28–
2.698 pg/ml) could be detected; and, despite the lack of Mtb resuscitation in granulomas
exposed to SEK, high amounts of IL-17A (942.8 pg/ml; 85.47–1281 pg/ml) were secreted by
most of the donors. Taken together, these results demonstrate the capacity of this human, in-
vitro granuloma model to identify the capability of TNF-α- and non-TNF-α-targeting biolog-
ics to differentially impact Mtb dormancy in a manner consistent with preclinical and clinical
observations.
Human, in-vitro granulomas reproduce the differential risk of LTBI
reactivation clinically observed with ADA or ETA
TNF-α plays a key role in the control of Mtb infection, yet the incidence of TB is higher in
patients receiving ADA compared to those receiving ETA [36,37]. Our results obtained from
granulomas exposed to these two biologics also suggested a preferential resuscitation of Mtb in
the context of ADA treatment. Consequently, we sought to decipher the mechanisms underly-
ing the differential interference of ADA and ETA with granuloma-induced Mtb dormancy in
Fig 2. Human, in-vitro granulomas corroborate risk of LTBI reactivation linked to treatment with TNF-α-targeting biologics. (A)
Percentages of auramine-O- (green) and Nile red-positive (red) Mtb quantified by fluorescence microscopy (mean ± SEM from 7 independent
donors) following 4 days of exposure with an isotype control (Iso), adalimumab (ADA), etanercept (ETA), ustekinumab (UST), anakinra
(ANA) or secukinumab (SEK). Statistical analysis was performed using a generalized linear mixed-effects model; n.s., not significant; �, p<0.05;
��, p<0.01; ����, p<0.0001. (B) Cytokine levels measured in supernatants of untreated in-vitro granulomas 8 days post-infection (median with
interquartile ranges, minimum and maximum values for 5 independent donors).
https://doi.org/10.1371/journal.ppat.1008312.g002
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an independent set of experiments. First, we characterized the kinetics of TNF-α accumulation
in order to assess the appropriateness of the antagonist treatment timing. The concentration of
TNF-α detected alongside the formation of untreated granulomas is depicted in Fig 3A. We
observed that the secretion of TNF-α occurs in two waves: an early secretion is detected within
the first 24h of infection which significantly wanes during the following days. A second wave
of TNF-α accumulates between 4 and 8 days post-infection, concurring with the duration of
the ADA and ETA treatment. From an additional set of donors, we confirmed that the pres-
ence of ADA significantly reverts dormant-like Mtb into metabolically-active (auramine-O-
positive) bacilli (Fig 3B). Compared to results depicted in Fig 2A, the effect of ETA appeared
less pronounced, yet remained always statistically significant when compared to the Iso- or
ADA-treated samples. This appeared to be the consequence of a decreased baseline ratio of
auramine/Nile red-positive bacteria induced upon granuloma formation in the absence of
drugs (Iso). Complementary results defining dormant-like Mtb phenotype were obtained by
Fig 3. Unequal interference of TNF-α-targeting biologics ADA and ETA with granuloma-induced Mtb dormancy does not relate to
differential bioavailability. (A) TNF-α concentration in supernatants on days 1, 4 and 8 post-infection with Mtb H37Rv (values for 7
independent donors are represented by line-connected circles and bars picture the mean concentration). Statistical analysis was performed using
a Wilcoxon paired test. (B-D) At day 4 post-infection, granulomas were exposed for four additional days to an isotype control (Iso), adalimumab
(ADA), or etanercept (ETA) at 10 ng/ml. (B) Percentages of auramine-O- (green) and Nile red-positive (red) Mtb quantified by fluorescence
microscopy (mean ± SEM from 9 independent donors). (C) Mtb bacterial load quantified by CFU assessment (values for 4 independent donors
are represented by line-connected circles and bars picture the mean concentration). Statistical analysis was performed using a paired t test. (D)
Percentage of rifampicin (Rif)-tolerant Mtb quantified by CFU (mean ± SEM from 2 independent donors). (E) Percentages of auramine-O-
(green) and Nile red-positive (red) Mtb quantified by fluorescence microscopy following four days of exposure to Iso (full squares), ADA (full
circles/continuous line), or ETA (open circles/dotted line) at the indicated concentrations (mean ± SEM from 2 independent donors). Unless
stated differently, statistical analysis was performed using a generalized linear mixed-effects model; n.s., not significant; �, p<0.05; ��, p<0.01;
���, p<0.001; ����, p<0.0001.
https://doi.org/10.1371/journal.ppat.1008312.g003
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measuring bacterial load (Fig 3C) and tolerance to rifampicin (Rif) (Fig 3D). Four days after
Mtb infection, in-vitro granulomas were exposed to ADA, ETA or the isotype control for four
additional days. In order to assess the percentage of Rif-tolerant Mtb, granulomas were treated,
or not, with 5 μg/ml Rif for three extra days followed by determination of CFU. As shown in
Fig 3B, exposure to ADA induced significant Mtb resuscitation reflected by a significantly
higher mycobacterial load (Fig 3C) and a lower percentage of Rif-tolerant bacilli when com-
pared to the isotype (Fig 3D). On the other hand, granulomas treated with ETA showed a
slightly lesser (although statistically significant) decrease in the load of Rif-tolerant Mtb (Fig
3D), but did not undergo significant changes in their bacterial burden (Fig 3C). Taken together
these results confirm again that, in accordance with clinical observations, ETA interferes sig-
nificantly less with granuloma-induced Mtb dormancy than ADA. Differences in the pharma-
cokinetic properties and bioavailability between these two TNF-α antagonists have been
proposed to account for this different propensity. To test this hypothesis, granulomas were
exposed to increasing concentrations of ADA or ETA (1, 10, 100, and 1000 ng/ml) prior to the
assessment of Mtb auramine-O/Nile red phenotypes. Our results reveal a dose-response effect
of ADA and ETA on the frequency of metabolically active bacteria between 1 and 10 ng/ml,
reaching a plateau beyond 10 ng/ml (Fig 3E). Even a 100-fold higher concentration of ETA
was not able to reach the level of Mtb resuscitation induced by ADA, suggesting that other
mechanisms are responsible for the differential rate of Mtb resuscitation in granuloma exposed
to ADA in comparison to ETA.
ADA specifically mediates TGF-β1-dependent resuscitation of dormant-
like Mtb within granulomas
We investigated whether other intrinsic differences between ADA and ETA could account for
their differential bioactivity. As shown for IFX, ADA could interact with tmTNF-α and trigger
reverse signaling and subsequent production of TGF-β1 by macrophages whereas ETA failed
to do so [38]. Consequently, we sought to decipher wether a selective induction of TGF-β1
could explain the increased propensity of ADA to revert granuloma-induced Mtb dormancy
compared to ETA. We first aimed to elucidate the nature of the cells potentially experiencing
tmTNF-α-mediated reverse signaling. Having selectively used CD4+ T-cell responders to PPD
in this study, we intuitively expected that T cells would be mainly responsible of the late wave
of TNF-α observed following granuloma formation. After an overnight incubation with brefel-
din A, uninfected or Mtb-infected PBMCs were released from the extracellular matrix at the
indicated time-points and analyzed by flow cytometry (S2 Fig). As shown in Fig 4, all investi-
gated cell types, encompassing macrophages (Fig 4A) as well as CD4+ (Fig 4B) and CD8+ T
cells (Fig 4C), were found to produce TNF-α 8 days post-infection.
Next, we quantified the induction of active-TGF-β1 in supernatants of granulomas exposed
to ADA, ETA or an isotype control (Fig 5A). A consistent, though very mild, accumulation of
active TGF-β1 was observed in ADA-treated wells compared to ETA or the isotype control.
We consequently aimed to address if such a concentration of TGF-β1 could interfere with
granuloma-induced Mtb dormancy and lead to mycobacterial resuscitation. Four days post-
infection, granulomas were treated with increasing concentrations of recombinant TGF-β1, in
combination or not with a TGF-β1-neutralizing antibody, and Mtb was recovered four days
later. As depicted in Fig 5B, the presence of exogenous TGF-β1 at 8 pg/ml was already suffi-
cient to significantly impact Mtb dormancy. In fact, Mtb resuscitation was maximal and
reached a plateau from 40 pg/ml of exogenous TGF-β1. In addition, the presence of a TGF-
β1-neutralizing antibody was able to prevent Mtb resuscitation for all TGF-β1 concentrations
tested. Taken together, even a slight increase within the picogram range suffices to significantly
TNF-α antagonists and M. tuberculosis resuscitation in granulomas
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interfere with Mtb dormancy within granulomas. To confirm that the enhanced rate of Mtb
resuscitation observed in granulomas exposed to ADA compared to ETA was indeed due to
the selective induction of TGF-β1, we investigated if the addition of a TGF-β1-neutralizing
antibody may specifically counteract ADA-related Mtb resuscitation. As shown in Fig 5C, neu-
tralization of TGF-β1 in granulomas exposed to ADA completely prevented Mtb resuscitation
observed in the presence of ADA alone. This phenomenon was found restricted to ADA as the
addition of the TGF-β1-neutralizing antibody did not impact the resuscitation of Mtb
observed in granulomas exposed to ETA. Finally, we tested whether the preferential resuscita-
tion of Mtb mediated by TGF-β1 in the presence of ADA may be due to its bivalence and, con-
sequently, to its selective capacity to promote reverse signaling via tmTNF-α cross-linking. To
do so, we generated Fab fragments of ADA (ADA-Fab) using immobilized papain (S3 Fig) and
compared Mtb resuscitation rates within granulomas exposed to ADA or ADA-Fab (concen-
tration normalized according to total TNF-α binding sites) in the presence or absence of the
TGF-β1-blocking antibody (Fig 5D). Interestingly, the rate of dormant-like Mtb in ADA-Fab-
treated granulomas was significantly higher than in granulomas exposed to ADA and, in fact,
comparable to granulomas treated with ETA. Confirming our observations depicted in Fig 5C,
neutralization of TGF-β1 almost completely prevented the resuscitation rate of Mtb associated
with ADA. In contrast, and as observed in the case of ETA treatment, the presence of TGF-
β1-blocking antibodies did not impact the frequency of auramine-O/Nile red-positive bacteria
in granulomas exposed to ADA-Fab (Fig 5D). This observation demonstrates that the biva-
lence of ADA is required to specifically induce TGF-β1-dependent resuscitation of Mtb within
granulomas.
Neutralization of ETA ligand LT-α leads to mild Mtb resuscitation
Another intrinsic difference between ADA and ETA is that only ETA can interact with TNF-α
as well as TNF-β, also known as LT-α [19]. Therefore, we aimed to elucidate the role of LT-α
in the regulation of Mtb dormancy in granulomas exposed to ETA. We first assessed the kinet-
ics of LT-α production upon formation of Mtb granulomas. As represented in Fig 6A, and in
contrast to TNF-α, LT-α only accumulated between 4 and 8 days post-infection. We then
interrogated the cellular source of LT-α production following formation of Mtb granulomas.
After an overnight incubation with brefeldin A, uninfected or Mtb-infected PBMCs were
Fig 4. Late TNF-α production by Mtb-induced granulomas originates from T cells as well as macrophages. Frequencies of TNF-α-producing
macrophages (A) and CD4+ (B) or CD8+ T cells (C) from uninfected PBMCs (UI) or granulomas 6 and 8 days post-infection with Mtb H37Rv (median
with interquartile ranges, minimum and maximum values for 4 independent donors). Statistical analysis was performed using Friedman test; �, p<0.05.
https://doi.org/10.1371/journal.ppat.1008312.g004
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Fig 5. ADA specifically mediates TGF-β1-dependent Mtb resuscitation. (A) Active TGF-β1 concentration in
supernatants of granulomas 8 days post-infection with Mtb H37Rv and after 4 days of exposure to either adalimumab
(ADA), etanercept (ETA) or an isotype control (Iso) (values for 4 independent donors are represented by line-
connected circles and bars depict mean concentration). Statistical analysis was performed using Friedman test. (B-D)
Averaged percentages of auramine-O- (green) and Nile red-positive (red) Mtb quantified by fluorescence microscopy
after 4 days of exposure to: (B) 0, 8, 40 or 200 pg/ml of recombinant TGF-β1 in the absence (full circles/continuous
line) or presence (open circles/dotted line) of a TGF-β1-blocking antibody (mean ± SEM from 3 independent donors);
(C) an isotype control (Iso), adalimumab (ADA), or etanercept (ETA) in the absence or presence of a TGF-
TNF-α antagonists and M. tuberculosis resuscitation in granulomas
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released from the extracellular matrix at the indicated time-points and analyzed by flow
cytometry (S2 Fig). We observed that both CD4+ (Fig 6B) and CD8+ (Fig 6C) T cells produce
LT-α in response to Mtb infection at 6 and 8 days post-infection. Finally, we investigated the
impact of LT-α neutralization on the the rate of dormant-like Mtb within granulomas. In
order to avoid potential side-effects originating from the bivalence of the antibody, we
generated Fab fragments of a specific anti-LT-α neutralizing antibody (α-LTα-Fab) using
β1-neutralizing antibody (+ α-TGF-β1) (mean ± SEM from 5 independent donors); and (D) ADA or ADA Fab
fragment (ADA-Fab) in the absence or presence of a TGF-β1-neutralizing antibody, ETA or Iso. Statistical analysis was
performed using a generalized linear mixed-effects model; n.s., not significant; �, p<0.05, ��, p<0.01; ���, p<0.001;
����, p<0.0001. For (B) all comparisons were performed against the untreated control. For (C-D) only the most
relevant comparisons were plotted for clarity reasons but results from all combinations are available on S2 Table,
panels A and B respectively.
https://doi.org/10.1371/journal.ppat.1008312.g005
Fig 6. ETA-specific interference with CD4+ and CD8+ T cell-derived LT-α sustains mild Mtb resuscitation. (A) LT-α
concentration in supernatants on days 1, 4 and 8 post-infection with Mtb H37Rv (values for 7 independent donors are represented
by lined-connected circles and bars depict mean concentration). (B-C) Frequencies of LT-α-producing CD4+ (B) and CD8+ T cells
(C) from uninfected PBMCs (UI) or granulomas 6 or 8 days post-infection with Mtb H37Rv (median with interquartile ranges,
minimum and maximum values from 4 independent donors). (D) Percentages of auramine-O- (green) and Nile red-positive (red)
Mtb quantified by fluorescence microscopy (mean ± SEM from 4 independent donors) after four days of exposure to either an
isotype control (Iso), etanercept (ETA) or the Fab fragments from adalimumab (ADA-Fab) or an anti-LT-α antibody (α-LTα-Fab).
Statistical analysis was performed using a generalized linear mixed-effects model; ���, p<0.001; ����, p<0.0001.
https://doi.org/10.1371/journal.ppat.1008312.g006
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immobilized papain (S3 Fig). We then compared the Mtb resuscitation rate within granulomas
exposed to ADA-Fab or α-LTα-Fab individually and in combination. Both Fab fragments
showed comparable activity to ETA (Fig 6D), pointing to an unexpected capacity of LT-α to
promote the development of dormant-like Mtb in granulomas. Interestingly, the combined
treatment of granulomas with ADA-Fab and α-LTα-Fab did not reveal an additive effect on
Mtb resuscitation (Fig 6D).
Discussion
Investigating the complex dynamic interplay between the host and the intracellular pathogen
Mtb has proven to be challenging. In particular, defining the conditions leading to reactivation
from LTBI has been the subject of numerous studies in various animal species and humans
[39]. The importance of CD4+ T cells, TNF-α, IFN-γ, IL-12p40, together with the IL-1/IL-1R1
pathway, in host resistance to intracellular Mtb infection is evident from animal models and
human inherited and acquired immunodeficiencies [40]. Still many questions remain unan-
swered concerning the importance of other host immunological factors for the control of
LTBI. In recent years, novel pathway-specific biotherapeutics leading to selective immunosup-
pression have become available for the treatment of inflammatory immune-mediated diseases
[41,42]. Logically, this partial immunosuppression has proven to come at the expense of an
increased susceptibility to particular viral, fungal or bacterial infections and triggered inquiries
into the significance of these immunological pathways concerning LTBI reactivation [43,44].
Eventually, only few cases of TB are being detected among patients treated with non-TNF-α-
targeting biologics raising ethical concerns on the relevance of LTBI pre-screening require-
ment and prophylactic antibiotic treatment with potentially hepatotoxic drugs [25,45]. How-
ever, clinical trials assessing these new compounds either excluded participants displaying
signs of LTBI, or compound labels systematically recommended LTBI screening and prophy-
lactic antibiotic therapy prior treatment initiation [46].
In search for a translational model mimicking the dynamic host-pathogen interplay in TB,
we focused on in-vitro Mtb dormancy and resuscitation as a preclinical surrogate model of
clinical latency and reactivation [5, 6]. Human, in-vitro granulomas induce several dormant-
like Mtb features, such as accumulation of triacylglycerides as intracellular lipid inclusions and
loss of acid fastness [28]. In this report, we present a compilation of evidence supporting the
relevance of granuloma-like structures induced upon Mtb infection of PBMCs from pre-
immune blood donors to corroborate the risk of TB infection associated with the use of TNF-
α- and some non-TNF-α-targeting biologics. Moreover, we showed that the in-vitro granu-
loma model constitutes a powerful tool to perform mechanistic investigations to dissect the
interaction between biologics and granuloma functionality.
Indeed, the conclusions presented here advanced our understanding of the underlying
mechanisms supporting the differential rate of LTBI reactivation in patients treated with ADA
and ETA despite targeting the same cytokine. In accordance with clinically available data,
ADA showed increased propensity for Mtb resuscitation when compared to ETA in in-vitro
granulomas. A computational model suggested that differences in the permeability and there-
fore diffusion into TB lesions could be responsible of this phenomenon [24]. However, our
data revealed that a 100-fold increase in the concentration of ETA could not match the level of
ADA-induced Mtb resuscitation suggesting that another mechanism is likely involved to
explain this differential activity. Our results demonstrate that a specific induction of TGF-β1 is
responsible for the increased rate of Mtb resuscitation concomitant with ADA treatment com-
pared to ETA. This finding is consistent with the fact that macrophage-derived TGF-β1 would
play a major role in TB immuno-pathogenesis [47] and that only antibodies can crosslink
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tmTNF-α and trigger reverse signaling leading to TGF-β1 production [38]. Additional RNA
interference experiments could attest if this activity relies on de-novo TGF-β1 production or
an increased conversion of the latent forms present in human serum. However, transfection of
in-vitro granulomas embedded in a matrix of collagen would be particularly challenging. Our
observations are also consistent with the fact that addition of exogenous TGF-β1 accelerates
Mtb replication in monocytes [48], while treatment with neutralizing antibodies or natural
inhibitors augments their capacity to control Mtb growth [49]. Complement-mediated lysis of
effector T cells that expressed surface TNF-α, described in rheumatoid arthritis and ankylosing
spondylitis patients [50], is unlikely playing a role in our model for our protocol uses de-com-
plemented human serum. Nonetheless, a reduction in effector T cells due to intrinsic TGF-β1
produced by tmTNF-α reverse signaling could add-up to regulation of macrophage functions
mediated by TGF-β1 and contribute to the preferential Mtb resuscitation in patients treated
with ADA compared to ETA. In line with this, and using an in-silico granuloma model, War-
sinske and collaborators proposed that the presence of TGF-β1 in granulomas inhibits killing
of infected macrophages by cytotoxic T cells [51]. Hence, concomitant neutralization of TGF-
β1 in patients under ADA therapy could be used to decrease the TB risk associated with this
treatment. Furthermore, since we found that TGF-β1 induction is directly linked to ADA biva-
lence, monovalent or bispecific neutralizing agents could constitute a safer option to prevent
the undesired induction of tmTNF-α reverse signaling.
Rather unexpectedly, we found that the specific neutralization of LT-α in the environment
of granulomas interfered with Mtb dormancy to the same extent than neutralization of TNF-α
mediated by ADA Fab fragments. We could not detect an additive activity of blocking both
TNF-α and LT-α. This may reflect that the receptor could still interact with one or the other
cytokine while bound to a Fab entity. As such, this may compete with the binding of the other
cytokine or indirectly prevent its signaling after internalization of the receptor. However, our
observations suggest that LT-α may play a stronger role than previously expected in the
immune function of granulomas and more specifically also contribute to the mild LTBI reacti-
vation risk associated to ETA. Indeed, the high susceptibility of TNF-α knock-out mice to Mtb
infection, despite expressing normal levels LT-α, led to the conclusion that LT-α was not
required for the immune response against mycobacteria [52]. Nonetheless, in the context of
BCG infection, reintroduction of a functional copy of the LT-α gene in TNF-α/LT-α double
deficient mice improved their survival [53]. Adding to the controversy, deficient chimeric
mice rather suggested an important role of soluble LT-α in the control of Mtb infection [54],
while the construction of LT-α knock-out mice able to produce normal levels of TNF-α
pointed to a minor role of LT-α in the control of chronic TB compared to the major role of
TNF-α in the control of acute Mtb infection [55].
Ultimately, we showed that granulomas exposed to biologics neutralizing cytokines poten-
tially important for the control of Mtb infection could variably impact the physiology of the
bacteria reflecting different potential to promote LTBI reactivation. Indeed, individual com-
pounds reproducibly showed variable activity on Mtb dormancy, ranging from none (SEK) to
moderate (ETA) and more active (ADA, UST and ANA). Regarding the activity linked to
ADA and ETA, it is well established that TNF-α plays a critical role in the control of Mtb pro-
liferation and granuloma formation [9–13]. Thus, unsurprisingly, the activity of ADA and
ETA observed in human in-vitro granulomas confirmed the observed risk of LTBI reactivation
concurrent to their usage in the clinic. The high activity of UST is in agreement with the previ-
ously described natural susceptibility to mycobacterial infections of humans carrying muta-
tions in the IL-12 pathway, activation of which is an important trigger of classical activation of
macrophages and induction and maintenance of protective IFN-γ-producing CD4+ T cells
[56, 57]. Although not as frequent as with ADA, cases of TB have been reported following UST
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therapy [45,58,59]. Despite barely detectable levels of IL-12p70 and IL-23, UST clearly reverts
Mtb dormancy (Fig 2A), demonstrating that the system is able to capture the consequences of
neutralizing a cytokine that does not accumulate. This is reminiscent of IL-10 which plays and
important role in controlling Mtb but may be challenging to detect due to low expression and
inherent instability [60]. IL-1RA, and hence ANA, binds non-productively the IL-1 receptor
inhibiting the activities of both IL-1α and IL-1β which are essential for the control of Mtb
infection in mice [61,62]. The activity observed with ANA is therefore expected and actually
consistent with a case report of TB reactivation observed in a rheumatoid arthritis patient
receiving this compound [63]. It is also supported by the proposed beneficial role of IL-1R1
signaling during TB infection that counteracts in a PGE2-dependent manner a detrimental
production of type I interferons [64]. Finally, the role of IL-17A, in the immune response dur-
ing TB remains controversial. Knock-out mice for IL-17RA appeared more susceptible to a
high-dose intra-tracheal infection with Mtb [65], whereas no differences in bacterial burden
were observed after a low-dose aerosol infection [66]. Despite IL-17A being actively released
upon in-vitro granuloma formation, the presence of SEK did not trigger Mtb resuscitation
within granulomas, supporting independently a previous report [35]. As reviewed recently
[67], PBMC-based, in-vitro granuloma models usually lack neutrophils, non-hematopoietic-
derived cells, vascularization, plasticity, and continuous influx of freshly recruited immune
cells, which constitute important limitations. Since not all cellular targets of IL-17A (e.g. neu-
trophils) are present in the Mtb-induced, in-vitro granulomas, a potential in-vivo effect of its
blocking cannot be completely ruled out. Nonetheless, a side-by-side comparison of the effects
of anti-IL-17A or anti-TNF-α neutralizing antibodies in a murine infection model, confirmed
the importance of TNF-α in the immune response against Mtb, in contrast to the IL-17 path-
way [68]. Altogether, to date, the composite of clinical, in-vivo and in-vitro data show a low
risk for mycobacterial infection under SEK therapy, in contrast to anti-TNF-α treatment [45].
From a translational safety assessment perspective, identification of drug-induced hazards
or infection risks has proven to be challenging for a number of reasons. First, the precise
nature of immune responses and built-in reserve capacity keeping commensal or pathogenic
microbes in check is not comprehensively understood. Secondly, time-dependent contribu-
tions of specific cytokines by polyfunctional immunocompetent cells are essential to multicel-
lular host responses in a protective immunity network [69], and hence complicate hazard and
risk assessments of the importance of single cytokines in the context of biotherapeutic safety
evaluations. While TNF-α, IL-12p40 and IL-1β are important cytokines for host resistance to
Mtb, the overall low incidence of TB cases observed in clinical studies with cytokine-specific
neutralizing antibodies suggests that susceptibility to reactivation of LTBI is determined by a
combination of factors rather than the deficiency of just one cytokine. For example, a func-
tional interdependence between IL-1β and TNF-α regulates TNF-α-dependent control of Mtb
infection [70]. Contrasting some of our interpretations, and despite few case reports in the
context of UST therapy, post-marketing surveillance data suggest that ANA and UST would
not significantly increase the risk of LTBI reactivation [17,71]. However, these conclusions
may be biased by the compounds’ labels which advise to perform LTBI testing prior to initiat-
ing treatment and, if positive, provide anti-TB prophylaxis which has been shown to reduce
drastically the advent of reactivation cases [72]. Our observations rather suggest that special
considerations should be taken in future, should these biologics access markets of low and
middle-income countries harboring higher TB incidence and where the use of such drugs
could also increase the risk of direct progression to disease following a primary infection.
In conclusion, the data presented here demonstrate the clinical translational relevance and
versatility of the human, in-vitro granuloma model by enabling mechanistic studies and allow-
ing comparative profiling of the impact of specific immunological pathways in the context of
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Mtb dormancy and resuscitation. Altogether our results support in-vitro granulomas as a valu-
able tool for preclinical evaluation of the risk of new biological therapies that could promote
LTBI reactivation. Given the length of treatment and potential side effects of drugs used for TB
preventive therapy [72], assessing preclinically this risk, and subsequent need for LTBI screen-
ing and prophylaxis, could eventually benefit clinical decision making and patient safety.
Materials and methods
Ethics statement
Human peripheral blood mononuclear cells were isolated from buffy coats obtained from the
Interregionale Blutspende SKR AG, Bern, Switzerland. All donors provided informed consent
which includes information on the use of blood products for research purposes (https://www.
jedonnemonsang.ch/fileadmin/pdf_form/Informationsblatt_Spender_2019_f.pdf).
Antibodies and reagents
Human IgG1 isotype control (Biolegend; clone ET901), anti-human TNF-α adalimumab
(Humira, Abbvie), soluble human TNFR2-Fc fusion protein etanercept (Enbrel, AMGEN),
anti-human IL-17A secukinumab (Cosentyx, Novartis) and anti-human IL-12p40 Ustekinu-
mab (Stelara, Janssen) were used at a final concentration of 10 ng/ml unless specified otherwise
in the figure. Recombinant IL-1RA anakinra (Kineret, Swedish Orphan Biovitrum) was used
at 1.15 ng/ml (equimolar). TGF-β1-neutralizing antibody (Biolegend; clone 19D8) was used at
1 μg/ml. Other antibodies were obtained from Biolegend if not stated differently. IFN gamma,
TNF alpha and TNF beta Human ProcartaPlex™ Simplex Kits (Invitrogen), Cytokine & Che-
mokine 34-Plex Human ProcartaPlex™ Panel 1A (Invitrogen) and Magnetic Luminex Perfor-
mance Assay TGF-beta 1 Kit (R&D Systems) were used for cytokine quantification.
Human peripheral blood mononuclear cells (PBMCs)
PBMCs were isolated by Ficoll-Paque (GE Healthcare) density-gradient centrifugation of
buffy coats from healthy blood donors (Interregionale Blutspende SKR AG, Bern, Switzer-
land), as per written informed consent. After two washings in RPMI medium (Sigma), PBMC
aliquots were cryopreserved in RPMI containing 10% DMSO (Sigma) and 40% fetal bovine
serum (FBS, Gibco) and stored in liquid nitrogen until use. When needed, PBMCs were
thawed, washed twice in RPMI containing 10% FBS and benzonase (12.5 U/ml, BioVision)
and rested in RPMI containing 10% FBS for at least 6 h at 37˚C (5% CO2). Sample viability
above 95% was assessed by trypan blue dye exclusion method and concentration adjusted to
107 cells/ml in RPMI containing 20% human serum (PAN-Biotech) (referred to as “cell culture
medium” from here on). To investigate the presence of CD4+ T cell memory response against
mycobacterial antigens, PBMCs were stimulated or not with ESAT-6/CFP-10/TB7.7 peptide
pool (Peptides & elephants, 1 μg peptide/ml final) or PPD (Statens serum institute, RT23,
10 μg/ml final) in the presence of Brefeldin A (Biolegend). After overnight incubation, PBMCs
were fixed and washed with intra-cellular staining buffers from Biolegend and stained with
anti-human CD3-FITC (clone OKT3); anti-human CD4-FITC (clone RPA-T4); anti-human
CD8a-APC (clone, HIT8a) and anti-human IFN-γ-PerCP (clone 4S.B3) before data acquisi-
tion on a BD FACSCalibur instrument and analysis using FlowJo10.5 (S1 Fig).
Isolation of PBMC subsets and fluorescent staining
Rested PBMCs were sequentially subjected to CD14 and CD4 selection using magnetic
microbeads (Miltenyi Biotec GmbH). Isolated monocytes and CD4+ T cells were next stained
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in orange and green, respectively, using Live Cell Tracking Kits (Abnova) as per manufactur-
er’s instructions, while the unselected PBMC subsets were left unstained. Finally, PBMCs were
reconstituted from the various fractions according to the proportion of CD14+ and CD4+ pop-
ulations in the initial sample.
M. tuberculosis (Mtb)
Mtb H37Rv was grown in 7H9 broth supplemented with 10% ADC (5% bovine albumin frac-
tion V, 2% dextrose and 0.003% catalase), 0.5% glycerol (AppliChem Panreac) and 0.1%
Tween-80 (Sigma) under gentle agitation to mid-exponential phase (OD600 approximately
0.6). Bacteria were then washed with PBS containing 0.1% Tween-80, re-suspended in cell cul-
ture medium, water-bath sonicated for 2 min and centrifuged at 260×g for 5 min. The upper
part of the supernatant (single-bacteria suspension) was recovered, cryopreserved by adding
5% glycerol (final) and stored at –80˚C until use. Concentration of the frozen stocks was quan-
tified by colony forming units (CFU) assessment.
3D in-vitro, Mtb-induced human granulomas
The human, in-vitro granuloma model developed by Kolattukudy and colleagues [28] was
adapted. Briefly, rested PBMCs were infected with Mtb at a multiplicity of infection (MOI) of
0.05 bacteria per monocyte, assuming 10% monocytes in PBMCs, and distributed in 24-well
plates at 2.5×106 PBMCs/well. An extracellular matrix (ECM) was prepared by mixing thor-
oughly 0.95 ml of PureCol collagen solution (Advanced BioMatrix), 50 μl of 10×DPBS (SAFC
Biosciences), 4 μl of fibronectin (Sigma), and 10 μl of 1N NaOH (Sigma) per ml of ECM
required and kept at 4˚C. The ECM solution was mixed with the infected PBMCs in a 1:1 ratio
(v/v) at room temperature (RT), and was allowed to set for 45 min at 37˚C (5% CO2). Once
the ECM completely set, wells were topped up with 500 μl of cell culture medium and incu-
bated at 37˚C (5% CO2). On day 4 post-infection, when relevant, supernatant was replaced by
the same amount of fresh cell culture medium containing the studied antibodies, biologics or
the isotype control. Granuloma formation was monitored on day 7–8 post-infection using a
Leica DM IL LED inverted microscope and a Leica MC170 HD camera (Leica).
Papain digestion and Fab-fragment purification
Fab fragments from adalimumab and an anti-LT-α antibody (clone 359-238-8) were generated
and purified using PierceTM Fab Micro Preparation Kit (ThermoFisher Scientific) as per man-
ufacturer’s instructions. Briefly, 50 μg of each antibody were diluted in Digestion Buffer and
desalted using ZebaTM Spin Desalting Columns prior to digestion with immobilized papain
for 6 h at 37˚C in an end-over-end mixer. The Fab fragments were then purified using NAbTM
Protein A Plus Spin Columns. Protein concentration was determined by measuring absor-
bance at 280 nm (using an estimated extinction coefficient of 1.4) and purity of the isolated
Fab fragments was confirmed in reducing SDS-PAGE and Coomasie blue staining (S3 Fig).
When used for the treatment of Mtb-induced granulomas, concentration was normalized
according to total TNF-α binding sites in adalimumab.
Dual auramine-O/Nile red staining of Mtb
At the specified time-points, supernatant was removed and wells were treated with 250 μl of
collagenase (1 mg/ml; Sigma) for 40 min at 37˚C (5% CO2) to release the PBMCs from the
ECM. Host cells were pelleted at 400×g for 5 min and lysed with 0.1% Triton X-100 (Sigma)
for 20 min at RT, followed by centrifugation at 6000×g for 5 min to obtain the Mtb pellet.
TNF-α antagonists and M. tuberculosis resuscitation in granulomas
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1008312 February 18, 2020 16 / 23
Bacilli were inactivated with 1× CellFIX (BD) for 20 min at RT. Fixed samples were put on
glass slides, air dried and heat fixed at 70˚C. Fluorescent acid-fast staining using TB Fluores-
cent Stain Kit M (BD) was performed in combination with neutral-lipid staining dye Nile red
(Sigma) [28]. Each sample was stained with auramine-O for 20 min, decolorized for 30 s, cov-
ered with Nile red (10 μg/ml) for 15 min and counterstained with potassium permanganate for
2 min, including gentle washes with distilled water between each step. Air-dried, stained slides
were mounted using Vectashield mounting medium (Vectorlabs) and examined using a Leica
DM5000 B fluorescence microscope (Leica). For quantification purposes, at least 200 bacteria
per sample were counted. Representative micrographs for auramine-O and Nile red-positive
Mtb are shown in S4 Fig.
Rifampicin (Rif) tolerance and CFU assessment
To evaluate Rif tolerance at day 8 post-infection, Mtb-infected PBMC exposed to 10 ng/ml of
adalimumab, etanercept or an isotype control for 4 days were either left untreated (control) or
treated with 5 μg/ml Rif and incubated at 37˚C (5% CO2) for 3 additional days as described
previously [28]. Then, Mtb was recovered after collagenase treatment and PBMC lysis and the
pellet was re-suspended in 1 ml of H2O containing 0.05% tween-80. To determine the number
of CFU, 10-fold serial dilutions were prepared in triplicate in PBS containing 0.1% tween-80
and plated on Middlebrook 7H11 agar plates supplemented with 0.5% glycerol and 10%
OADC (0.05% oleic acid in ADC). The percentage of Rif tolerance was calculated by using the
formula: %Rif tolerance = CFU(Rif-treated)/CFU(untreated)×100.
RNA isolation and gene expression analysis by qRT-PCR
At day 8 post-infection, Mtb was recovered from in-vitro granulomas after collagenase treat-
ment and Triton X-100 lysis. The bacterial pellet was resuspended in TRI-reagent (Zymo
Research) and stored at –80˚C until RNA extraction. The TRI-reagent suspension was trans-
ferred into Beadbug tubes containing 0.1 mm silica beads (Sigma) and bead-beaten for 45 s at
6.5 m/s using a FastPrep-24 (MP Biomedicals). After removing the cellular debris by centrifu-
gation, total RNA was extracted from the bacterial lysate using Direct-zol RNA MiniPrep
(Zymo Research) according to the manufacturer’s protocol. Total RNA was treated with
DNAse I (Invitrogen), purified using RNeasy MinElute Cleanup Kit (Qiagen) and reverse
transcribed using FIREScript RT cDNA Synthesis Mix (Solis Biodyne) as per manufacturer’s
instructions. Expression of icl1, gltA1, nuoB, ctaD and 16S rRNA were quantified by qPCR
using Hot FIREpol EvaGreen qPCR Mix Plus (ROX) (Solis Biodyne) in a StepOnePlus real-
time system (Applied Biosystems). The details (sequences and references) of the primers used
are provided in S1 Table.
Cytokine measurements
Supernatants were collected at the specified time-points and stored at –80˚C until filter-sterili-
zation and analysis within 24 h. Concentrations of selected cytokines were determined using
magnetic-bead arrays (see Antibodies and Reagents) on a Luminex Bio-Plex 200 platform and
Bio-Plex Manager 6.0 software (Bio-Rad) according to the manufacturer’s recommendations.
Flow cytometry analysis
Host cells were recovered from the ECM after an overnight incubation with brefeldin A (Biole-
gend) and collagenase treatment at the indicated time-points and pelleted at 400×g for 5 min
as described above. Cells were then stained with anti-human CD40-FITC (clone 5C3), anti-
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human CD206-PE (clone 15–2), anti-human TNF-α-PerCP (clone MAb11) and anti-human
HLA-DR-APC (clone L243) (macrophages) or anti-human CD3-FITC (clone OKT3), anti-
human CD4-FITC (clone RPA-TA), anti-human LT-α-PE (clone 359-81-11), anti-human
TNF-α-PerCP (clone MAb11) and anti-human CD8α-APC (clone HIT8a) (T cells) following
a standard protocol. Briefly, cells were incubated in 50 μl of PBS containing 1% FBS and 1 μl of
each of the antibodies against extracellular markers for 20 min at RT. Samples were washed
once with PBS containing 1% FBS, fixed in Fixation buffer (Biolegend) for 20 min at RT and
washed twice with 1× Intracellular staining permeabilization wash buffer (ICS perm/wash
buffer, Biolegend). Cells were then incubated in 50 μl of 1× ICS perm/wash buffer containing
1 μl of each of the antibodies against intracellular markers for 30 min at RT, washed once with
1× ICS perm/wash buffer and fixed in 1× CellFIX for 20 min at RT. At least 50,000 events per
sample were acquired on a BD FACSCalibur™ instrument using CellQuest Pro software (BD)
and processed using FlowJo 10.5.
Quantification and statistical analysis
GraphPad Prism 7 or R.3.5.1 and R studio 1.1.456 were used to generate quantitative graphical
representation of the generated data and statistical tests. The number of independent donors
used (biological replicates), nature of the tests and definition of center and dispersion mea-
sures is specified within the respective figure legend. A single technical replicate per donor and
condition was tested to generate each figure; with the exceptions of Fig 3B were up to five tech-
nical replicates were cumulated depending on the donor, and Fig 3C were all the conditions
were tested in duplicates. For all figures significance was defined as: n.s., not significant; �,
p<0.05, ��, p<0.01; ���, p<0.001; ����, p<0.0001.
Supporting information
S1 Fig. Immunization status of the blood donors selected for the study. PBMCs were stimu-
lated overnight with Mtb protein purified derivative (PPD) or a synthetic peptide pool from
ESAT-6, CFP-10 and TB7.7 Mtb proteins and analyzed by flow cytometry. (A) Representative
dotplots of the gating strategy. (B) Background-subtracted frequencies of IFN-γ-producing
CD4+ T cells for each donor selected for the study. The response was considered positive when
more than 0.05% of cytokine-producing cells were detected within the CD4+ T cell parent pop-
ulation and this frequency was at least twice higher than the background level detected in the
absence of stimuli.
(TIF)
S2 Fig. Gating strategy used to detect TNF-α- or LT-α-producing cell types within Mtb-
induced granuloma. Representative dotplots showing the gating strategy used to focus on
HLA-DR+ macrophage (A) or CD4+ and CD8+ T cell populations (B).
(TIF)
S3 Fig. SDS-PAGE analysis of undigested and papain-digested Fab fragments from ADA
and anti-LT-α antibodies. SDS-PAGE and Coomasie blue staining of adalimumab (ADA)
(A) or an anti-LT-α antibody (B) and their purified Fab fragments (ADA-Fab and α-LT-α-
Fab, respectively).
(TIF)
S4 Fig. Representative micrographs for auramine-O and Nile red staining. Mtb H37Rv
recovered from granulomas 8 days post-infection and after 4 days of exposure to either adali-
mumab, etanercept or an isotype control.
(TIF)
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S1 Table. Sequences and references of the primers used for qPCR.
(PDF)
S2 Table. Statistical analysis of Fig 5C and 5D. Statistical analysis was performed using a gen-
eralized linear mixed-effects model; n.s., not significant; �, p<0.05, ��, p<0.01; ���, p<0.001;
����, p<0.0001.
(PDF)
S1 Data. Raw data used to generate the figures on this manuscript. Each row contains the
values from one independent donor.
(XLSX)
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